Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice.
5-fluorouracil infusion
bevacizumab
clinical practice
intensive chemotherapy regimen
metastatic colorectal cancer
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
17
4
2019
pubmed:
17
4
2019
medline:
17
4
2019
Statut:
epublish
Résumé
Several trials evaluated the role of intensive regimens, made of triplet chemotherapies plus bevacizumab, as first-line treatment for patients with metastatic colorectal cancer (mCRC). We previously reported, in a Phase II prospective study, the efficacy and the tolerability of FIrB/FOx regimen, reporting interesting results in terms of received dose intensities (rDIs) and safety. We reported a retrospective update of 85 patients treated with FIrB/FOx, an intensive regimen of 5-fluorouracil, bevacizumab, and weekly alternate irinotecan and oxaliplatin, to confirm its feasibility in "real life". Subgroup analyses were performed, particularly among patients treated with standard and modified FIrB/FOx (based on age, performance status, and/or comorbidities). Overall, 3-month objective response rate (ORR) and 6-month ORR were 75.9% and 55.3%, respectively. Median progression-free survival (PFS) and median overall survival (OS) were 14.4 and 34.9 months, respectively. Among the patients treated with standard and modified regimens, 3-month ORR, PFS, and OS were 75.8% and 76% ( This update shows that intensive regimens such as FIrB/FOx are also feasible options for first-line treatment of mCRC patients in the "real-life" setting.
Sections du résumé
BACKGROUND
BACKGROUND
Several trials evaluated the role of intensive regimens, made of triplet chemotherapies plus bevacizumab, as first-line treatment for patients with metastatic colorectal cancer (mCRC). We previously reported, in a Phase II prospective study, the efficacy and the tolerability of FIrB/FOx regimen, reporting interesting results in terms of received dose intensities (rDIs) and safety.
METHODS
METHODS
We reported a retrospective update of 85 patients treated with FIrB/FOx, an intensive regimen of 5-fluorouracil, bevacizumab, and weekly alternate irinotecan and oxaliplatin, to confirm its feasibility in "real life". Subgroup analyses were performed, particularly among patients treated with standard and modified FIrB/FOx (based on age, performance status, and/or comorbidities).
RESULTS
RESULTS
Overall, 3-month objective response rate (ORR) and 6-month ORR were 75.9% and 55.3%, respectively. Median progression-free survival (PFS) and median overall survival (OS) were 14.4 and 34.9 months, respectively. Among the patients treated with standard and modified regimens, 3-month ORR, PFS, and OS were 75.8% and 76% (
CONCLUSION
CONCLUSIONS
This update shows that intensive regimens such as FIrB/FOx are also feasible options for first-line treatment of mCRC patients in the "real-life" setting.
Identifiants
pubmed: 30988620
doi: 10.2147/OTT.S194745
pii: ott-12-2159
pmc: PMC6438145
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2159-2170Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
J Clin Oncol. 2001 May 1;19(9):2413-21
pubmed: 11331320
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
J Clin Oncol. 2005 Jun 1;23(16):3706-12
pubmed: 15867200
Br J Cancer. 1992 Jul;66(1):39-45
pubmed: 1637674
Br J Cancer. 2006 Mar 27;94(6):798-805
pubmed: 16508637
Oncol Rep. 2006 May;15(5):1345-50
pubmed: 16596209
J Clin Oncol. 2007 May 1;25(13):1670-6
pubmed: 17470860
Cancer Chemother Pharmacol. 2008 Jul;62(2):195-201
pubmed: 17901955
J Clin Oncol. 2008 Apr 20;26(12):2013-9
pubmed: 18421054
J Clin Oncol. 2008 Jul 20;26(21):3523-9
pubmed: 18640933
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Ann Oncol. 2009 Nov;20(11):1842-7
pubmed: 19406901
Oncology. 2009;77(2):113-9
pubmed: 19628950
J Clin Oncol. 2009 Dec 10;27(35):5931-7
pubmed: 19884549
Oncol Rep. 2010 Jun;23(6):1635-40
pubmed: 20428819
Int J Cancer. 2011 May 1;128(9):2075-84
pubmed: 20635392
Lancet Oncol. 2010 Sep;11(9):845-52
pubmed: 20702138
BMC Cancer. 2010 Oct 19;10:567
pubmed: 20958992
Br J Cancer. 2010 Nov 9;103(10):1542-7
pubmed: 20959822
Oncologist. 2011;16(11):1557-64
pubmed: 22016477
Clin Colorectal Cancer. 2012 Dec;11(4):229-37
pubmed: 22694897
BMC Cancer. 2012 Aug 16;12:356
pubmed: 22897915
Cancer Res. 1990 Jan 1;50(1):197-201
pubmed: 2293556
Br J Cancer. 2012 Dec 4;107(12):1932-7
pubmed: 23169296
Ann Oncol. 2013 Aug;24(8):2062-7
pubmed: 23666916
N Engl J Med. 2013 Sep 12;369(11):1023-34
pubmed: 24024839
BMC Cancer. 2014 Jul 19;14:521
pubmed: 25038824
N Engl J Med. 2014 Oct 23;371(17):1609-18
pubmed: 25337750
Ann Oncol. 2015 Apr;26(4):702-8
pubmed: 25538173
J Clin Oncol. 2015 Mar 1;33(7):692-700
pubmed: 25605843
Br J Cancer. 2015 Sep 15;113(6):872-7
pubmed: 26335608
Lancet Oncol. 2015 Oct;16(13):1306-15
pubmed: 26338525
Int J Clin Exp Med. 2015 Oct 15;8(10):18713-20
pubmed: 26770486
Clin Adv Hematol Oncol. 2017 Jan;15(1):22-24
pubmed: 28212365
BMC Cancer. 2017 Jun 9;17(1):408
pubmed: 28599628
J Clin Oncol. 1995 Jun;13(6):1303-11
pubmed: 7751875
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
J Clin Oncol. 1998 Apr;16(4):1582-7
pubmed: 9552069